Introduction
Rapidly proliferating cells require a continual supply of oxygen and nutrients. When tissue growth surpasses the ability of the surrounding vessels to deliver these requirements, oxygen deprivation, or hypoxia, occurs. Hypoxia initiates a variety of cellular responses including activation of proto-oncogenes and subsequent angiogenesis. This process is critical to growth and metastasis of tumor cells (Folkman, 1992 (Folkman, , 2002 Ellis and Fidler, 1996) . The most studied of the peptides that promote angiogenesis is vascular endothelial growth factor (VEGF), also known as vascular permeability factor (VPF) (Senger et al., 1983; Leung et al., 1989; Shweiki et al., 1992; Namiki et al., 1995) . VEGF is a potent angiogenesis promoter and is overexpressed in numerous human cancers including pancreatic, colon, and prostate carcinomas (Takahashi et al., 1995; Itakura et al., 1997; Jackson et al., 1997) . VEGF enhances migration, proliferation, and reverses senescence of endothelial cells, thus stimulating blood vessel formation (Guo et al., 1995; Senger et al., 1996; Watanabe et al., 1997) .
Many signal transduction pathways have been implicated in promoting VEGF expression. Activation of the protein tyrosine kinase, c-Src, and/or its downstream mediator phosphatidyl-inositol 3-kinase (PI3K), have been extensively studied for their roles in promoting VEGF expression (Mukhopadhyay et al., 1995; Eliceiri et al., 1999; Alvarez-Tejado et al., 2001) . In both tumor and normal cells, hypoxia causes a rapid increase in the activity of the Src (Namiki et al., 1995; Ellis et al., 1998) . Transfection of cells with the activated form of Src (vSrc) resulted in elevated levels of HIF-1a and VEGF expression under normoxic conditions, with further activation occurring under hypoxic conditions, while downregulation of c-Src reduces both VEGF expression, tumor growth and tumorigenicity in murine models (Fleming et al., 1997; Jiang et al., 1997; Staley et al., 1997; Wiener et al., 1999) .
The precise signaling pathway(s) by which Src regulates VEGF expression by hypoxia remain(s) unclear. Src and PI3-kinase activation lead to increased expression and stability of the transcription factor hypoxia-inducible factor-1a (HIF-1a), which plays a critical role in regulating VEGF transcription (Forsythe et al., 1996; Jiang et al., 1997; Chan et al., 2002; Karni et al., 2002) . In normoxia, the von Hippel-Lindau protein (pVHL) rapidly degrades subunits of HIF-1a by targeting it for the ubiquitin-proteasome pathway (Iliopoulos et al., 1996; Maxwell et al., 1999; Ivan et al., 2001) . HIF-1a protein levels and transcriptional activity are negatively regulated by O 2 -dependent hydroxylation (Iliopoulos et al., 1996; Ivan et al., 2001; Lando et al., 2002) . Under hypoxic conditions, activated HIF-1a translocates to the nucleus and dimerizes with HIF-b (also known as aryl hydrocarbon receptor nuclear translocator (ARNT)) and associates with the coactivators p300 or CBP. The HIF-1 heterodimer binds to a hypoxia response element (HRE) in the promoter and enhances transcription of the downstream gene (Forsythe et al., 1996; Jiang et al., 1996) .
More recently, signal and transducer of transcription 3 (STAT3) activation has been shown to mediate VEGF transcription (Niu et al., 2002b; Wei et al., 2003) . Src phosphorylates STAT3, and this phosphorylation is essential for the ability of v-Src to transform cells (Yu et al., 1995; Turkson et al., 1998) . Activation of gene transcription by STAT3 also requires its dimerization, but unlike HIF-1a, STAT3 forms homodimers and under some circumstances heterodimers with STAT1 (Bromberg and Darnell, 2000; Calo et al., 2003) . Latent STAT3 is cytoplasmic but phosphorylation leads to dimerization, nuclear translocation, and activation of target genes including VEGF (Schaefer et al., 1999; Niu et al., 2002b; Wei et al., 2003; Yahata et al., 2003) . Hypoxic activation of STAT3 has not been previously determined, although the STAT family member STAT5 undergoes hypoxic activation (Joung et al., 2003) .
Interestingly, while both HIF-1a and STAT3 have been shown to regulate VEGF expression and are activated by Src, potentially cooperative control of the VEGF promoter by each of these factors has not been investigated. The STAT3-binding site is 86 bp downstream from the HIF-1-binding site (Forsythe et al., 1996; Wei et al., 2003) . In addition, both HIF-1a and STAT3 bind the transcriptional coactivator CBP/p300, suggesting that if simultaneous occupancy of the VEGF promoter occurs, they may be part of a single transcriptional complex (Arany et al., 1996; Schuringa et al., 2001) . We report here for the first time that exposure of cells to cobalt chloride (CoCl 2 ), which mimics the hypoxic induction of Src, results in activation of the VEGF promoter through binding of both HIF-1 and STAT3. Inhibition of the binding of either transcription factor significantly reduces VEGF expression. In addition, we show that HIF-1a physically associates with STAT3, CBP/p300, and Redox effector factor-1/apurinic/apyrimidinic endonuclease (Ref-1/Ape). We demonstrate that optimal transcriptional control of the VEGF promoter requires binding of both HIF-1 and STAT3, and these factors are part of a large transcriptional complex coordinated in part by the coactivators CBP/p300 and Ref-1/APE.
Results

Activation of Src, HIF-1a, and STAT3 by hypoxia
To determine the effect of hypoxia upon Src activation in pancreatic and prostrate cancer cells, cultured cells were exposed to CoCl 2 (100 mM) as a mimic to hypoxia (Minchenko et al., 1994) , or CoCl 2 with the Src inhibitor PP2 (10 nM) for 18 h. As shown in Figure 1a , hypoxia increases Src phosphorylation on tyrosine 418, indicative of increased Src activation in the pancreatic cancer cell line PANC-1 and prostrate cancer cell line PC-3 (B2-fold increase relative to control in both cell lines), while the Src inhibitory PP2 blocks this activation (B50% decrease relative to control). Next, the effect on HIF-1a was determined. As also shown in Figure 1a , while HIF-1a is expressed at normoxia in PANC-1 and PC-3 cells, its levels significantly increase in response to hypoxia (B4.5-8-fold induction). Inhibition of endogenous c-Src activation in PANC-1 and PC-3 cells by PP2 drastically reduced HIF-1a levels to below those levels observed at normoxia (Figure 1a ). STAT3 has also been implicated in VEGF expression (Niu et al., 2002b) , but its potential activation by hypoxia is yet to be determined. As shown in Figure 1a , STAT3 is expressed in PANC-1 and PC-3 cultured cells under 
Expression of activated Src increases HIF-1a levels and phosphophorylated STAT3
The previous experiments implicated Src activation in the observed changes in HIF-1a and STAT3. To determine more directly if Src activation is causal for increased steady state levels of HIF-1a and STAT3 phosphorylation in PANC-1 and PC-3 cells, subclones in which activated chicken SrcY527F could be induced by doxycycline were created as described in Materials and methods. Incubation of these PANC-1 and PC-3 subclones with doxycycline (2 ng/ml) for 24 h induced activated Src expression (Figure 2 ). Accompanying the expression of activated Src, HIF-1a levels increased substantially over controls (PANC-1 B8-fold induction; PC-3B4.5-fold induction). Likewise, activated Src led to increased levels of phosphorylated STAT3 (PANC-1 and PC-3, B2-3-fold increase) relative to controls (Figure 2 ).
Src-mediated nuclear translocation of STAT3 and HIF-1a
Activation of HIF-1a and STAT3 results in nuclear translocation of each factor. To determine if Src activation led to this translocation, immunohistochemistry was performed on Src-activated cells utilizing an anti-HIF-1a antibody and an antibody, which recognizes activated STAT3 (phospho-STAT3). Prior to Src activation in PANC-1 tet-on Src-527 cells, both HIF-1a and phospho-STAT3 were diffusely located throughout the cell with little staining of either factor observed in the nucleus (Figure 3a and b) . Src activation resulted in complete nuclear translocation of all HIF-1a ( Figure 3a ) and phospho-STAT3 (Figure 3b ). To determine if HIF1a affected STAT3 nuclear translocation or vice versa, cells were transiently transfected with an HIF-1a or an STAT3 dominant negative plasmid (pCEP4/HIF-1a-DN or STAT3-Y705F, respectively), each of which interferes with DNA binding of its target factor. The dominant negative HIF-1a protein, which has a mutated DNA domain, has previously been shown to reduce HIF transcription by competing with endogenous HIF-1a for its required transactivation partner HIF-1b. Interruption of STAT3 transactivation was accomplished through expression of a DNA-binding-defective STAT3 protein, which prevents STAT3 DNA binding and subsequent transcription when dimerized with endogenous STAT3 (Forsythe et al., 1996; Kaptein et al., 1996; Yahata et al., 2003) . In PANC-1 cells in which activated Src was induced, expression of HIF-1a-DN caused a distinct diffusion of its target factor from the nucleus to the cytoplasm (Figure 3a ), but did not affect phospho-STAT3 nuclear localization ( Figure 3b ). Likewise, prevention of phospho-STAT3 association with its respective DNA element caused a similar nucleus to cytoplasm diffusion (Figure 3b ), but did not affect HIF1a localization ( Figure 3a ). Morphologic changes characteristic of expression of activated Src were observed, but this morphology was not altered by transfection with the respective dominant negative constructs. These data show that expression of activated Src results in HIF-1a and activated STAT3 nuclear translocation, and retention of each factor is not dependent upon translocation and/or retention of the other. We also show that presumptive prevention of dimerization and DNA binding by each targeted factor results in subcellular relocalization only of that specific factor. STAT3 and HIF-1a localization to the nucleus Figure 2 Effect of induction of activated Src on HIF1a expression and STAT3 phosphorylation. Parental, empty vector controls, or tet-on Src-527-expressing cells lines were grown and incubated with and without doxycycline (2 ng/ml) 24 h prior to cell lysis as described in Materials and methods. Expression of activated Src was ascertained by immunoblotting with an avian-specific Src antibody (EC-10). In addition, immunoblotting with HIF-1a, phospho-STAT3, and total STAT3 was performed. Immunoblots were reprobed with an antibody to vinculin as a loading control following CoCl 2 treatment were confirmed by fractionation experiments. Prior to CoCl 2 treatment, unphosphorylated STAT3 is found exclusively in the cytosol. Following 6 h CoCl 2 treatment, only phospho-STAT3 is observed and only in the nuclear fraction ( Figure 3c ). HIF-1a expression is low prior to CoCl 2 treatment and after treatment expression is primarily in the nucleus.
Hypoxia or expression of activated Src results in both HIF-1a and STAT3 binding to the VEGF promoter
Both HIF-1 and STAT3 have been implicated in mediating VEGF transcription (Niu et al., 2002b) , but the simultaneous binding of each transcription factor to the VEGF promoter by Src activation or hypoxia has not been examined. The HIF-1 regulatory region of the VEGF promoter (À985 to À935 bp) contains a STAT3 element 86 bp downstream that has been implicated in VEGF transcription (Forsythe et al., 1996; Wei et al., 2003) . To determine if Src-dependent increase in HIF-1a levels and phosphorylation of STAT3 results in either or both nuclear factors associating with the VEGF promoter in vivo, chromatin immunoprecipitation (ChIP) assays were utilized. Fractionated chromatin from controls and CoCl 2 -treated (to mimic hypoxia) or Src-activated tet-on PANC-1 and PC-3 cultured cells were immunoprecipitated with antibody to HIF-1a or STAT3, and the immunoprecipitates isolated. From the isolated DNA, a 350-bp region was amplified by PCR for 30 cycles. In normoxic conditions, no detectable HIF-1a and STAT3 was associated with the VEGF promoter in controls and the untreated tet-on SrcY527F cells in PANC-1 (Figure 4a ) and PC-3 cells (Figure 4b ) or in PANC-1 and PC-3 cells treated with CoCl 2 (Figure 4c ). By increasing PCR cycles to 50, some HIF-1a binding, but no STAT3 binding was detected (data not shown). Activation of Src in either the PANC-1 and PC-3 cell lines by the addition of doxycycline (2 ng/ml for 24 h) showed a considerable increase of HIF-1a and STAT3 associating with the VEGF promoter ( Figure 4a , b, lanes 7 and 9). Similar binding of HIF-1a and STAT3 was observed in PANC-1 and PC-3 cells incubated with CoCl 2 (Figure 4c , lanes 3 and 5, 7 and 9, respectively). These data demonstrate that hypoxia (as mimicked by CoCl 2 ) and expression of activated Src both lead to simultaneous binding of HIF1a and STAT3 on the VEGF promoter fragment. Induction of VEGF expression by hypoxia or activatedSrc requires HIF-1a and STAT3 binding to the VEGF promoter for optimal activity
Next, we determined the individual effects of STAT3 and HIF-1a on VEGF transcription and protein production. For these experiments, PANC-1 and PC-3 cells were transiently transfected with a luciferase reporter plasmid that contained 2.2 kb of the VEGF promoter from cells stimulated by CoCl 2 or doxycycline (tet-on Src527 clones) for 24 h. CoCl 2 and induction of activated Src in tet-on Src527 clones each induced similar levels of luciferase activity (B10-fold) relative to controls (Figure 5a , b, first two columns). ELISA quantization of VEGF production in the supernatant of cells incubated with CoCl 2 or doxycycline to induce activated Src showed concomitant increases in VEGF protein (Figure 5c , d, first two columns). These data support previous studies that hypoxic activation of Src (as mimicked by CoCl 2 ) is a central regulatory factor in VEGF production (Minchenko et al., 1994) . Coincubation of doxycycline-treated Src tet-on Src527 clones with CoCl 2 showed no significant change in promoter activity and VEGF production compared to individual treatment (data not shown), further suggesting that Src is central to VEGF expression. Since our data demonstrates that both HIF-1a and STAT3 bind to the VEGF promoter following Src activation, we examined the absolute requirement of each nuclear factor in VEGF regulation in PANC-1 and PC-3 cells. To interrupt VEGF transcription by these factors, we cotransfected with the VEGF-luciferase promoter reporter plasmid alone as a control, or the reporter plasmid and either a dominant negative HIF-1a (pCEP4/HIF-1a-DN) or STAT3 dominant negative expression plasmid (STAT3-Y705F). The cotransfected PANC-1 or PC-3 cells were subjected to CoCl 2 treatment or activation of Src by the addition of doxycycline (tet-on Src-527 clones). Repression of either HIF-1a or STAT3 function by expression of the appropriate dominant negative construct decreased luciferase activity three fold with respect to expression of activated Src alone (Figure 5a , b), and reduced VEGF expression to basal levels ( Figure  5c , d). Thus, both functional HIF-1a and STAT3 are required for maximal VEGF activity. Recently, STAT3 has been reported to form heterodimers with STAT1 (Bromberg and Darnell, 2000; Calo et al., 2003) . While STAT1 is expressed in both PANC-1 and PC-3 cells, it is not phosphorylated under hypoxic conditions (data not shown). Thus, the transcriptional changes observed in VEGF expression are likely to result predominantly from STAT3 homodimers.
The VEGF transcriptional complex contains HIF-1a, p300, STAT3, and Ref-1/APE
The HIF-1-binding site in the VEGF promoter is at À985 to À935, while the STAT3-binding site is 86 bp downstream at À849 to À842 (Forsythe et al., 1996; Niu et al., 2002b; Wei et al., 2003) . Owing to the proximity of the two sites, we sought to determine if HIF-1a and STAT3 were components of the same transcriptional complex. As both HIF-1a and STAT3 have been reported to associate with transcriptional coactivator CBP/p300, we used nuclear extracts from PANC-1-uninduced and activated Src-induced cells to determine if HIF-1a, p300, and STAT3 coimmunoprecipitated (Ebert and Bunn, 1998; Gu et al., 2001; Schuringa et al., 2001; Ray et al., 2002) . As shown in Figure 6 , nuclear extracts immunoprecipitated with antibody to p300 (Figure 6a ) or HIF-1a (Figure 6b ), coimmunoprecipitated with STAT3, with increased association in extracts from Src-induced cells. Extracts immunoprecipitated ChIP assays were performed as described above on lysates from PANC-1 and PC-3 cells (approx 1.0 Â 10 10 cells each) treated with or without CoCl 2 (100 mM) for 16 h with an anti-phospho-STAT3 antibody and probed with HIF-1a also showed a similar increase in association following Src activation (Figure 6c) . Recently, it has been reported that Ref-1/Ape, which is a cotranscription factor in addition to being a DNA repair enzyme, may be a necessary component of HIF-1a transcription complex (Carrero et al., 2000; Ziel et al., 2004) . To ascertain if Ref-1/APE is part of the STAT3/HIF-1a/ p300 complex, nuclear extracts were immunoprecipitated by Ref-1/APE and probed for STAT3 coimmunoprecipitation (Figure 6d ). These data demonstrate that HIF-1a, STAT3, CBP/p300, and Ref-1/APE are all likely present in the same complex on the VEGF promoter.
Discussion
Angiogenesis is a vital step in the continued growth and progression of tumors and intratumoral hypoxia is a principal regulator of angiogenesis (Semenza, 2002) . One of the most critical proangiogenic peptides induced by hypoxia is VEGF, and expression of VEGF correlates with poor prognosis in a number of human tumors (Ishigami et al., 1998; Fontanini et al., 2002) . Cells were seeded in 12-well plates (0.25 Â 10 6 cells/well) and grown in complete media. Following a 24 h recovery period, cells were transfected with 200 ng of VEGF reporter plasmid and either 1.3 mg of pCEP4 (control wells), 1.3 mg of HIF-1a-DN plasmid (HIF-1a dominant negative), or 1.3 mg of STAT3-DN (STAT3 dominant negative) plasmid as indicated. Cells were treated 16 h later with CoCl 2 (100 mM) or doxycycline for 24 h at which time the medium was removed and stored at À801C for ELISA and cells were lysed. Aliquots (20-ml) of each sample were analysed for luciferase expression and expressed as RLU. Relative luminescence was calculated as average luciferase activity (RLU)/ protein concentration. All transfections were performed in triplicate. Asterisks denote significant differences (Po0.05) from columns with activated Src and treatment with CoCl 2 (c) VEGF expression in culture supernatants of PANC-1 cells and (d) PC-3 cells. From the above-described conditions, the medium was removed from cells and stored at À801C. VEGF in the culture supernatants was determined by ELISA as described in Materials and methods. Asterisks denote significant differences (Po0.05) from columns with activated Src and treatment with CoCl 2 IP-p300 Probe STAT3 -Dox + Dox VEGF expression is believed to be predominantly regulated by the transcription factor HIF-1a, which in turn is regulated by signaling pathways initiated by molecules including growth factors and cytokines (Zelzer et al., 1998; Thornton et al., 2000; Liu et al., 2002; Mayerhofer et al., 2002; Semenza, 2003) . Alterations in these signal transduction cascades in tumor cells can lead to constitutive expression of VEGF in normoxic conditions, primarily through activation of the PI3-kinase, MAP kinase, and Src pathways (Harris, 2002; Semenza, 2003) . Activation of the PI3-kinase and MAP kinase pathways leads to increased rates of HIF1a translation, although this may be cell type dependent (Semenza, 2003; Bardos and Ashcroft, 2004) . Activated Src (either v-Src or Src with activating mutations) has been implicated in both HIF-1a stabilization and increased translation depending on the model system examined (Jiang et al., 1997; Chan et al., 2002; Karni et al., 2002) . The protein tyrosine kinase activity of Src also rapidly increases following hypoxia, and SrcÀ/À fibroblasts are greatly diminished in their capacity to induce VEGF expression in response to this stress (Mukhopadhyay et al., 1995) . In colon cancer cells with activated Src, both constitutive and hypoxia-inducible expression of VEGF are increased (Fleming et al., 1997; Ellis et al., 1998) . As Src leads to activation of the PI3-kinase/Akt pathway in a number of tumor cells, increased VEGF expression may occur through this pathway (AlvarezTejado et al., 2001) . In addition to increasing the expression of HIF-1a, Src also regulates phosphorylation of STAT3. This phosphorylation is required for transformation of fibroblasts by v-Src, and STAT3 phosphorylation is increased in many tumor cells with high Src activity (Yu et al., 1995; Cao et al., 1996; Bromberg et al., 1998) . Recently, STAT3 has also been implicated as a positive regulator of VEGF transcription (Niu et al., 2002b; Wei et al., 2003) . In this study, we examined the relationship between Src activation, HIF1a expression, and STAT3 phosphorylation with respect to regulation of VEGF expression.
IP-HIF-1α
Our results show that incubation of cells by CoCl 2 (which mimics hypoxia) results in activation of STAT3 and HIF-1a, and inhibition of Src activation by the addition of the selective Src-family inhibitor, PP2, blocks this activation. Induction of activated Src (by a tet-on system) in PANC-1 and PC-3 cells increased VEGF expression, steady-state HIF-1a levels, and phosphorylation of STAT3, as was observed in cells incubated with CoCl 2. When cells in which activated Src had been induced were incubated with CoCl 2, no further significant increases in VEGF expression was observed, although we cannot discount that there may be additive or synergistic effects with CoCl 2 treatment (data not shown) that are undetected. These results suggest that Src activation is a significant component of hypoxiainduced expression of VEGF.
Previous studies have suggested that HIF-1a or STAT3 alone are capable of activating VEGF transcription (Niu et al., 2002b; Buchler et al., 2003; Stoeltzing et al., 2003; Wei et al., 2003) . Our data suggest that hypoxia-mediated VEGF expression requires binding of both STAT3 and HIF-1a to the VEGF promoter for maxium induction in pancreatic and prostate carcinomas. As we have shown, expression of either a dominant negative STAT3 or HIF-1a reduces promoter activity significantly, suggesting that loss of binding by either transcription factor compromises VEGF expression, and may negate any synergistic effect conferred by both factors on VEGF production. In ChIP analysis on PANC-1 cells, increasing the PCR cycles from 30 to 50 showed that small amounts of HIF-1a binding to VEGF promoter prior to stimulation, while no STAT3 bound to its prospective element (data not shown). Basal transcription of the VEGF promoter has been proposed to require HIF-1a (Forsythe et al., 1996; Buchler et al., 2003) . However, it has been suggested that maximum induction of HIF-1 target genes requires functional interactions between HIF-1 and other transcription factors (Pugh et al., 1994; Ebert and Bunn, 1998; Semenza, 2003) . Investigation of hypoxic activation of the LDH-A gene showed that two binding sites, an HIF and a CREB-1/ATF-1 site, are required for expression (Firth et al., 1995; Ebert and Bunn, 1998) . The Endothelin-1 (ET-1) gene is induced by hypoxia and also requires two tandem binding elements, an HIF-1 and an adjacent AP-1-binding site (Yamashita et al., 2001) . Our data provide further support that activation by HIF requires an adjacent transcription factorbinding site, and may help to explain tissue-specific differences observed in HIF-mediated induction of some transcripts by various stimuli (Semenza, 2003; Bardos and Ashcroft, 2004) .
We also show that HIF-1a and STAT3 coimmunoprecipitate with CBP/p300 and Ref-1/APE, and levels of coimmunoprecipitation increase with Src activation (Figure 6 ). These results suggest that HIF-1a and STAT3 are components of a large complex governing transcription of VEGF. The coactivator p300 binds to a variety of transcription factors including STAT3 and HIF-1a, and is a critical component in hypoxicregulated HIF-1a transcriptional complexes (Yuan et al., 1996; Zhang et al., 1996; Lill et al., 1997; Ebert and Bunn, 1998; Kallio et al., 1998; Paulson et al., 1999; Schuringa et al., 2001; Yamashita et al., 2001) . Gene activation by p300 is controlled in part by its ability to bind upstream transcription factors, such as those in the composite VEGF regulatory element, and coordinate this complex with the basal transcription machinery (Abraham et al., 1993; Merika et al., 1998; Nakashima et al., 1999) Curran, 1992; Carrero et al., 2000; Ziel et al., 2004) , but prior to this study has not been shown to physically associate with STAT3. Src activation thus results in increased activity of HIF-1a and STAT3, which translocate to the nucleus and in conjunction with Ref-1/APE bind to the composite regulatory element in the VEGF promoter. This complex may lead to the recruitment of p300, which serves as a platform for other components of the transcription complex, which together activate gene expression.
Finally, our results suggest one potential mechanism by which Src may contribute to tumor progression. Src activity often increases during tumor progression and may be predictive of poor prognosis (Talamonti et al., 1993; Summy and Gallick, 2003) . By regulating both STAT3 activation and HIF-1a expression, increasing Src activity may augment the hypoxic response in VEGF expression, itself a prognostic marker in many tumors (Hartenbach et al., 1997; Niedergethmann et al., 2002; Nam et al., 2004; Uehara et al., 2004) . In addition to enhancing angiogenesis, hypoxia-mediated activation of HIF-1a and STAT3 may also contribute to increased tumorigenic properties in pancreatic and prostrate carcinomas. HIF also regulates invasion and cell survival (Semenza, 2003) , while STAT3 activation is associated with increased cell proliferation and survival (Niu et al., 2002a) . These properties, combined with increased angiogenesis, can result in a more aggressive cancer and suggests that Src, as well as HIF-1a, STAT3, or Ref-1/APE will provide valuable molecular targets for combating the growth and metastasis of human tumors.
Materials and methods
Cell lines and cell culture conditions
The adenocarcinoma PANC-1 cell line and the prostate carcinoma PC-3 cell line were purchased from ATCC (Manassas, VA, USA) and maintained in either MEM (PANC-1) or F-12/DMEM (PC-3) supplemented with 10% FBS, 2.0 mM L-glutamine, and penicillin/streptomycin (Life Technologies, Inc., Grand Island, NY, USA), at 371C with 5% CO 2 .
Generation of activated Src TET-on cell lines
TET-On cells lines were created using the TET-On system (Clontech, Palo Alto, CA, USA) according to the manufacturer's protocol. 1 Â 10 6 subconfluent PANC-1 and PC-3 cells were transfected with the pTet-On plasmid. DNA (1 mg) was prepared with 6 ml of Fugene 6 according to the manufacturer's directions. At 24 h after transfection, the medium was removed and cells were washed with 371C PBS, then supplemented with complete media containing 600 mg/ml (PANC-1 cells) or 300 mg/ml (PC-3 cells) of G418 (Invitrogen/Life Technologies) for selection. Single colonies were isolated and expanded for further analyses by transient transfection of the pTRE-Luc and treated for 24 h with 2 mg/ml doxycycline. The pTRE plasmid DNA was linearized with BamH1 and treated with Klenow DNA polymerase, followed by digestion with SalI. A 1.8 kb Src-527 cDNA was excised from pRSV-Src527 plasmid (Kmiecik and Shalloway, 1987) with Not1 (followed by Klenow treatment) and Xho1 digestions. The cDNA was ligated into pTRE yielding pTRE-Src527. Clones of PC-3 and PANC-1 expressing the highest level of luciferase activity were cotransfected with pTRE-Src527 and selected with hygromycin B (250 mg/ ml PANC-1 and 100 mg/ml PC-3) in complete media with G418. Stable clones were screened for Src 527 expression by immunoblot analysis after 24 h doxycycline treatment using a chicken-Src-specific antibody (EC-10). Control clones cotransfected with pTRE and selected with Hygromycin B and G418 of each cell line were also obtained.
Transient expression assays
PANC-1 and PC-3 cells were maintained in culture as described. All plasmid DNA used in transfections was prepared using Qiagen plasmid DNA isolation kits according to the manufacturer's instructions. For luciferase assays, 2 days prior to transfection 0.125 Â 10 6 cells were plated per well in 12-well plates supplemented with complete media. Immediately prior to transfection, cells had 250 ml of fresh media added to each well. All cells were transfected with a total of 1.5 mg of DNA using Fugene-6 reagent (Roche, Mannheim, Germany) following the manufacturer's protocol. DNA used was as follows: 200 ng of VEGF luciferase reporter plasmid (2.2 kb) combined with either 1.3 mg of pCEP4 (control wells), 1.3 mg of HIF-DN plasmid (Forsythe et al., 1996) , or 1.3 mg of STAT3-DN plasmid. Cells were washed with 371C PBS 4 h after transfection and 2 ml of complete media was added to each well. Following a 16-h recovery period, cells were treated with doxycycline (Src tet-on system cells 0.2 mg/ml) or CoCl 2 (100 mM) in complete media. Following a 24-h incubation, the medium was removed and stored at À801C for VEGF production analysis. Cells were washed in PBS and lysed in 100 ml of Promega passive lysis buffer. Luciferase activity was determined by using 20 ml of cell extract that was mixed with 100 ml of luciferase assay reagent (Promega, Madison, WI, USA) and placed in a luminometer (Monolight 2010). Light production was measured twice for 10 s and expressed as RLU, and all transfections were performed in triplicate. Relative luciferase activity was calculated as average luciferase (RLU)/ mg protein content as measured by the Bradford assay (BioRad, Hercules, CA, USA).
ELISA
VEGF production in culture supernatants was examined using a human VEGF-specific ELISA (Quantikine; R&D Systems, Minneapolis, MN, USA) normalized to total protein content as measured by Bradford assay.
Immunofluorescence microscopy
At 2 days prior to transfection 5000 cells were plated per chamber in an eight-chamber slide. All cells were transfected with a total of 1.0 mg of DNA (pCEP4, HIF-1a-DN, of STAT3-DN) using Fugene-6 reagent as previously described. Following a 16-h recovery period, cells were treated with doxycycline (2 mg/ml) or PBS (control) for 24 h. Cells were then fixed with 37% formaldehyde in PBS, permeabilized in PBS containing 0.5% Triton X-100 and 1% bovine serum albumin (BSA), and blocked with 10% fetal bovine serum (FBS) in PBS. Cells were incubated with 1 : 50 anti-HIF-1a (BD Transduction Laboratories, San Jose, CA, USA) or an anti-STAT3 (Cell Signaling) antibody diluted in blocking solution. Cells were washed and incubated with fluorescein (FITC)-or Texas-Red-conjugated anti-mouse or anti-rabbit IgG antibody (Molecular Probes, Eugene, OR, USA) diluted 1 : 100. Nuclei were stained with Hoechst 33342 at 1 mg/ml (Molecular Probes, Eugene, OR, USA). Cells were examined using a fluorescent microscope (Nikon Microphot-FXA).
Immunoblot assays
Cells were grown to a confluencey of 85-90% in complete media and solublized in 20 mM Tris-Cl (pH 8.0), 137 mM NaCl, 1% Triton X-100, 1 mM Na 3 VO 4 , 2mM EDTA, with 1 complete Mini Protease Inhibitor Cocktail Tablet (Roche Diagnostics, Basel, Switzerland). Nuclear extracts were prepared by adding 1 ml of cell lysis buffer (10 mM HEPES-KOH, pH 7.9; 1.5 mM MgCl 2 ; 10 mM KCL; 0.5 mM DTT). Cells were lysed with a Dounce homogenizer (B-type pestle) at 41C, centrifuged and the resulting pellet was resuspended in 1.5 ml of nuclear lysis buffer (20 mM HEPES-KOH, pH 7.9; 25% v/v glycerol; 0.42 M NaCl; 1.5 mM MgCl 2 ; 0.2 mM EDTA; 0.5 mM PMSF; 0.5 mM DTT) and incubated at 41C for 30 min. Nuclear extracts were concentrated with 0.35 mg/ml of solid sodium, centrifuged and resuspended in 0.5 ml of 41C suspension buffer (20 mM HEPES-KOH, pH 7.9; 20% v/v glycerol; 1.5 mM KCl; 0.2 mM EDTA; 0.5 mM PMSF; 1 mM DTT). Dialysis of the purified nuclear extract in 500 ml of buffer D at 41C was preformed for 5 h followed by storage of the extract at À801C. Immunoblot analysis of total cellular extract utilized 50 or 500 mg for immunoprecipitations, while analysis of nuclear extracts utilized 50 mg of lysates. Protein concentrations were determined by Bradford assay. Immunoprecipitations were performed in 500 ml of 20 mM Tris-Cl (pH 8.0), 137 mM NaCl, 1% Triton X-100, 1 mM Na 3 VO 4 , 2 mM EDTA, 1 complete Mini Protease Inhibitor Cocktail Tablet, and 1.0 mg of 11 antibody and rotated overnight at 41C. Antibody-Protein complexes were isolated following 2 h incubation with 25 ml of protein A/G. Lysates were fractionated by 8% SDS-PAGE, transferred to PVDF membrane (Amersham Corp., Arlington Heights, IL, USA), and probed with either anti-Phospho-Src 416, anti-STAT3, anti-Phospho-STAT3 (Ser 705) (Upstate Biotechnology Inc., Lake Placid, NY, USA), or anti-HIF-1a (BD Biosciences, Franklin Lakes, NJ, USA). Antibodies were diluted in Tris-buffered saline-0.1% Tween 20 (v/v) with 5% dried milk. Peroxidase-conjugated secondary antisera, goat anti-mouse antisera (BioRad, Hercules, CA, USA), or goat anti-rabbit (Bio-Rad) were used to detect the respective primary antibodies. Immunoreactive proteins were visualized with Chemiluminescence Reagent Plus detection system (NEN, Boston, MA, USA).
ChIP assay
Cells (approx 1.0 Â 10 10 ) were grown to a confluencey of 85-90% in complete media and treated with or without doxycycline (2 mg/ml) or 100 mM CoCl 2 (to mimic hypoxia) for 24 h. Cells were treated with 1% formaldehyde for 10 min at room temperature (RT), followed by the addition of 2 M glycine to a final concentration of 0.125 M. Cells were washed in 41C PBS and pelleted in 1 ml of lysis buffer (5 mM PIPES, 85 mM KCL, 0.5% NP-40, and protease inhibitors) and incubated for 10 min at À201C. Cells were pelleted and nuclei resuspended in 0.5 ml of nuclei lysis buffer (50 mM Tris-CL, pH 8.0, 10 mM EDTA, 1% SDS, and protease inhibitors) and incubated for 10 min at À201C. Nuclear lysates were sonicated (Sonic Dismembrator 60, Fisher Scientific) for five 3-s intervals on ice to shear DNA to 0.800-1.2 kb fragments. Chromatin solutions were precleared with salmon sperm/protein A agarose-50% slurry (Upstate Biotech.) while rotating at 41C for 15 min. Precleared supernatant were incubated with anti-STAT3, HIF-1a, or no Ab (negative control) and rotated overnight at 41C. Chromatin/protein complex were isolated with 15 ml of Staph A cells. Chromatin was purified by adding 1 ml RNAase A (10 mg/ml), NaCL (0.3 M final concentration) and incubating at 671 for 6 h, followed by phenol chloroform extraction and ethanol precipitation. The region À1386 to À1036 of the VEGF promoter was PCR amplified from the immunoprecipitated chromatin using the following primers: sense 5 0 -CAGGTCAGAAACCAGCCAG, antisense; 5 0 -CGTGATGATTCAAACCTACC. The 350-bp PCR product was resolved on a 1.2% agarose gel and visualized by ethidium bromide staining and UV illumination. Positive controls for all reactions utilized chromatin sonicated as described above, and were phenol/chloroform extracted followed by ethanol precipitation.
Quantitation of autoradiograms
Autoradiographs were quantified in the linear range of the film by scanning the image using a Hewlett Packard Scanjet scanner and quantitated with Scion Image software program. Each sample measured was calculated as the ratio of the average area over the average area of actin or vinculin for immunoblots or as the ratio above the average area of basal/ control levels of the protein of interest in immunoprecipitations.
Statistical analyses
Statistical analyses were performed using InStat 2.01 statistical software (GraphPad Software, San Diego, CA, USA) using the Student's t test, or Fisher's Exact test, where appropriate. Significance was determined with 95% confidence.
Abbreviations VEGF, vascular endothelial growth factor; STAT3, signal and transducer of transcription 3; HIF, hypoxia inducible factor.
